ID
15643
Description
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Relapse Evaluation Visit No. 2
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Keywords
Versions (1)
- 6/6/16 6/6/16 -
Uploaded on
June 6, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Relapse Evaluation Visit No. 2: Relapse Confirmation Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit No. 2: Relapse Confirmation Relapse Multiple Sclerosis ALAIN01 NCT02419378
Similar models
Relapse Evaluation Visit No. 2: Relapse Confirmation Relapse Multiple Sclerosis ALAIN01 NCT02419378
C0750484 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])